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in a meta-analysis of all case-control studies. In addition,
 ALOX5AP  gene expression levels were determined in con-
trols and IS cases.  Results: A first meta-analysis of both sub-
sets showed that the T allele of the SG13S114 SNP in  ALOX5AP 
was a risk factor for IS after Bonferroni correction [OR = 1.22 
(1.06–1.40); p = 0.006]. A second meta-analysis of white pop-
ulations confirmed these results [OR = 1.18 (1.07–1.31); p = 
0.001].  ALOX5AP gene expression analysis in a subset of con-
trols and cases revealed that the SG13S114 genotypes modu-
late mRNA levels of  ALOX5AP  (p = 0.001) and mRNA levels 
were higher in IS cases (2.8  8 2.4%) than in controls (1.4  8 
1.3%; p = 0.003). No association of the variants in  PDE4D with 
IS was observed in our study.  Conclusions: The  ALOX5AP 
SG13S114 variant is an independent risk factor for IS in the 
Iberian population and is associated with  ALOX5A P expres-
sion levels. The role of this gene in stroke merits further in-
vestigation. 
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 Abstract 
 Background: Variants in the 5-lipoxygenase-activating pro-
tein  (ALOX5AP) and phosphodiesterase 4D  (PDE4D) genes 
have first been associated with ischemic stroke (IS) through 
whole-genome linkage screens. However, association stud-
ies obtained conflicting results. We aimed to investigate the 
contribution of selected single nucleotide polymorphisms 
(SNPs) in these genes for the first time in a large Iberian pop-
ulation.  Methods: A case-control design was used to analyze 
one SNP in  ALOX5AP and five SNPs in  PDE4D in a total of 1,092 
IS patients and 781 healthy controls of two different sub -
sets from Spain and Portugal. The analysis was adjusted
for confounding variables and the results were integrated
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 Introduction 
 Environmental and genetic factors contribute to the 
development of complex diseases such as ischemic stroke 
(IS), the leading cause of disability and third cause of 
death in developed countries  [1, 2] . The DeCode study 
highlighted the implication of single nucleotide poly-
morphisms (SNPs) and haplotypes in the 5-lipoxygen-
ase-activating protein ( ALOX5AP or  FLAP ) and phos-
phodiesterase 4D  (PDE4D) genes in IS in the Icelandic 
population through genome-wide linkage scan  [3–5] . 
The study showed that a haplotype in the ALOX5AP 
gene, HapA defined by the SNPs SG13S25, SG13S114, 
SG13S89 and SG13S32, conferred an increased risk of 
suffering myocardial infarction and stroke  [5, 6] . More-
over, several SNPs in the PDE4D gene (SNP41, SNP45, 
SNP56, SNP87 and SNP89) were strongly associated 
with the combined cardioembolic and atherothrombotic 
stroke subtypes. A risk haplotype was also described, 
composed of SNP45 and microsatellite AC008818-1, 
which conferred a risk about 1.8 times higher of suffering 
stroke to the 16% of the general population that carries 
at least one copy  [4] .
 However, replication of these results in other popula-
tions has proven difficult. Concerning the ALOX5AP 
gene, 4 studies in European populations confirmed later 
the association with stroke  [6–9] , whereas 4 studies and a 
meta-analysis did not  [10–14] . Concerning the PDE4D 
gene, 14 studies have been published as follow-up in Eu-
ropean populations, 11 of which claimed replication of 
the findings  [10–13, 15–21] and 3 did not  [7, 22, 23] . Sta-
ton et al.  [17] , in 2006, observed a significant association 
with IS of SNP41, SNP83 and SNP87 through meta-anal-
ysis. On the contrary, in a more recent and complete me-
ta-analysis on 5,200 and 6,600 stroke patients and con-
trols, respectively, it was shown that none of the genetic 
variants studied was robustly and reproducibly associat-
ed with stroke, when the data from the original report 
was excluded  [24] . Interestingly, Nilsson-Ardnor et al. 
 [16] , in 2005, published a study on a candidate region 
linkage approach for stroke in families from Sweden and 
replicated the linkage of the  PDE4D region on chromo-
some 5q.
 This study aimed to investigate the contribution of ge-
netic variants in the  ALOX5AP and  PDE4D to IS through 
a three-step approach: a large case-control analysis in the 
never tested before Iberian population, a meta-analysis of 
all case-control studies available for white ethnicity in-
cluding our results, and functional studies of selected ge-
netic variants.
 Material and Methods 
 Study Population 
 We used a case-control design on two datasets, from Spain 
and Portugal. Spanish IS cases were unrelated consecutive pa-
tients who were admitted to the Emergency Department of
University Hospitals throughout Spain, recruited within the first 
3 h after symptom onset. Only patients with a nonlacunar IS in-
volving the vascular territory of the basilar or middle cerebral 
arteries were included. Occlusion was assessed by transcranial 
Doppler ultrasonography  [25] . Control participants were healthy 
volunteers older than 65 years with no neurovascular and cardio-
vascular history, as well as family history of stroke, ascertained 
by direct interview before recruitment. Portuguese IS cases were 
unrelated patients, who were under the age of 65 at stroke onset 
and were recruited throughout Portugal. Stroke was defined by 
the presence of a new focal neurological deficit, with an acute 
onset and symptoms and signs persisting for more than 24 h, and 
confirmed by computed tomography scan and/or magnetic reso-
nance imaging  [26] . Control participants were healthy volunteers 
free of stroke as ascertained by direct interview before recruit-
ment. In both subsets, patients with a clinically known inflam-
matory or malignant disease were excluded from the study. De-
tails on socioeconomic and demographic characteristics were 
obtained from all subjects by questionnaires, together with infor-
mation on smoking, dyslipidemia, hypertension, diabetes melli-
tus and current medication use. A pooling-data analysis was per-
formed, based on the minimal available data for each study. 
Smoking was defined as ever smoking by interview. Hyperten-
sion was defined as systolic blood pressure  6 140 mm Hg and 
diastolic blood pressure  6 85 mm Hg, self-reported history and/
or treatment for hypertension. Diabetes mellitus was defined by 
self-reported history and/or any treatment for diabetes type 2. 
Dyslipidemia was defined as increased lipid concentrations (cho-
lesterol  1 200 mg/dl or triglycerides  1 200 mg/dl), self-reported 
history and/or any treatment for dyslipidemia. Informed written 
consent was obtained from all subjects and the local Ethics Com-
mittee approved the study. All subjects were of European white 
ancestry.
 Genetic Analysis 
 One SNP in the ALOX5AP gene (SG13S114) and five SNPs
in the PDE4D gene (SNP41, SNP45, SNP56, SNP87, SNP89) were 
investigated. These polymorphisms were genotyped using the 
SNPlex TM (Applied Biosystems, Inc., Foster City, USA), Seque-
nom  iPLEX, or TaqMan  (Applied Biosystems) technologies.
 Statistical Methods 
 Sample size for adequate power was calculated using the Ene 
2.0 software. Deviation from the Hardy-Weinberg equilibrium 
(HWE) was assessed using a   2 -test with 1 degree of freedom. A 
  2 or Fisher’s exact test, as appropriate, was used to compare cat-
egorical variables between groups. Continuous variables were 
compared between groups with the Student’s t test. Bonferroni 
correction was used to adjust for multiple comparison testing. 
The odd ratios (ORs) and 95% confidence intervals (CIs) for the 
effect on IS risk were estimated by logistic regression analysis ad-
justed for the effects of classical stroke risk factors. SPSS © 15.0 was 
used for all statistical analyses.
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 Meta-Analysis 
 Systematic review of the literature was performed in order to 
calculate the association of several SNPs with IS through meta-
analysis. Studies published up to December 31st, 2008 on the as-
sociation between ALOX5AP genetic variants and the risk of IS 
were identified in the MEDLINE database through the following 
terms: ALOX5AP, FLAP, lipoxygenase, polymorphism, gene, 
stroke, cerebral infarction, mutation, genotype, cerebrovascular 
disease, allele. Articles were included in the meta-analysis if the 
language was English, French or Spanish, and if the population 
studied was of White ethnicity. Data for analysis were extracted 
independently from each study by two investigators. The SNPs 
included in the meta-analysis were genotyped in at least 2 inde-
pendent studies and if data were available for our own dataset, it 
was also included. Between studies heterogeneity was estimated 
with the I 2 of Higgins and Thompson, and I 2  1 0.50 or p value 
 ! 0.05 were considered indicators of inconsistency between stud-
ies. Nonetheless, test for association was calculated in all cases 
with a random effects model from DerSimonian and Laird. The 
statistical tools used for the analysis were downloaded from the 
Critical Appraisal Skills Program at www.redcaspe.org. ORs were 
used to compare distributions of alleles and genotypes between 
cases and controls.
 Gene Expression Analysis 
 RNA was extracted from all available samples, 19 healthy con-
trols and 22 IS cases, in which blood was obtained at baseline (less 
than 3 h after onset of stroke symptoms) in the Vall d’Hebron Hos-
pital. Two EDTA tubes were centrifuged at 3,500 rpm for 15 min 
to obtain the white blood cell fraction, which was immediately 
preserved in RNA later  (Ambion  , Foster City, USA) at –80   °   C, 
and total RNA was isolated by RiboPure-Blood TM Kit (Ambion). 
cDNA synthesis was performed using High-Capacity cDNA Ar-
chive Kit (Applied Biosystems, Inc., Foster City, Calif., USA). 
mRNA levels were determined by quantitative Real Time PCR, us-
ing a standard TaqMan PCR kit protocol and TaqMan fluorogen-
ic probes with a 7500 Real Time PCR System (Applied Biosystems). 
The probes were located in the ALOX5AP (Hs00233463_m1) and 
the Cyclophilin A (PPIA) genes (Hs99999904_m1); the latter ran 
as housekeeping gene to normalize the results. All reactions were 
run in triplicate on three 96-well plates, using a unique sample as 
endogenous calibrator control in each one, and analyzed using the 
Applied Biosystems SDS 7500 system software. The results are 
expressed in percent depending on a healthy calibrator sample 
used in the experiments.
 Results 
 Case-Control Study 
 Sample size was calculated to obtain a power of 0.80 
with a significance level of 0.05 using the data from the 
two original Icelandic studies  [4, 5] . The mean risk allele 
frequency of the 6 SNPs (SG13S114 of  ALOX5AP and 
SNP41, SNP45, SNP56, SNP87, SNP89 of  PDE4D ) was 
calculated in cases (77.7%) and in controls (68.4%). Based 
on this average 10% difference in risk allele frequency be-
tween cases and controls, we calculated the sample size 
necessary for each subset, considering that we had ap-
proximately the same number of cases and controls avail-
able in the Portuguese dataset, and approximately half 
the number of controls than cases in the Spanish subset. 
The minimal sample size necessary was then 216 controls 
and 504 cases in the Spanish subset and 309 cases and 309 
controls in the Portuguese subset, with an expected theo-
retical effect size OR of 1.67 (1.16–2.39). Finally, 263 con-
trols and 527 cases from Spain and 518 controls and 565 
cases from Portugal were included in the analyses. Estab-
lished risk factors, including male gender, diabetes mel-
litus, hypertension and cigarette smoking were observed 
at a higher frequency in the IS group. On the other hand, 
dyslipidemic status did not differ between cases and con-
trols ( table 1 ).
 One SNP in  ALOX5AP  and five SNPs in  PDE4D were 
examined for association with IS. Genotype frequencies 
differed significantly from those predicted by the HWE 
in the control group for SNP45 of  PDE4D  in the Portu-
guese study ( table 2 ). Considering an additive model, be-
Table 1.  Baseline characteristics of IS cases and controls
Spain Portugal O verall
controls
(n = 263)
IS cases
(n = 527)
p value controls
(n = 518)
IS cases
(n = 565)
p value controls
 (n = 781)
IS cases
(n = 1,092)
p value
Age, years 72.186.9 70.6811.9 0.072 63.086.8 52.489.3 <0.001* 66.088.1 61.2814.0 <0.001*
Men, n (%) 121 (45.7) 287 (54.5) 0.019* 238 (45.9) 361 (63.9) <0.001* 359 (45.8) 648 (59.3) <0.001*
Smokers, n (%) 42 (15.8) 130 (25.9) 0.001* 146 (28.7) 272 (48.9) <0.001* 188 (24.3) 402 (38.0) <0.001*
Hypertension, n (%) 119 (44.7) 308 (59.2) <0.001* 192 (37.7) 289 (57.2) <0.001* 311 (40.1) 597 (58.2) <0.001*
Diabetes mellitus, n (%) 19 (7.1) 121 (23.1) <0.001* 58 (11.7) 95 (17.7) 0.007* 77 (10.1) 216 (20.4) <0.001*
Dyslipidemia, n (%) 81 (30.5) 173 (33.1) 0.445 325 (63.0) 328 (62.4) 0.834 406 (51.9) 501 (47.8) 0.082
Data are mean 8 SD or number (%). Statistically significant p values are marked with an asterisk.
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fore and after adjusting for the confounding variables 
age, gender, diabetes mellitus, cigarette smoking and hy-
pertension, the T allele of the SNP89 in  PDE4D was a risk 
factor for IS in the Spanish subset, but this association 
could not be replicated in the Portuguese sample. How-
ever, in the Portuguese subset, the T allele of the SG13S114 
SNP in  ALOX5AP was a risk factor for IS (OR = 1.21, 95% 
CI: 1.01–1.46, p = 0.037) and this association remained 
significant after adjusting for the different confounding 
variables (OR = 1.30, 95% CI: 1.01–1.68, p = 0.041). There 
was also a tendency for association in the Spanish subset 
(OR = 1.22, 95% CI: 0.98–1.53, p = 0.070). Overall, the 
pooling-data analysis revealed that the T allele of the 
SG13S114 was a risk factor for IS before (OR = 1.22, 95% 
Table 2.  Association results of PDE4D and ALOX5AP with IS in the Spanish and Portuguese subsets
Gene dbSNP ID ID Allele HWE in 
controls
p value
Frequency
controls
%
Frequency
cases
%
Crude OR
(95% CI)
Crude
p value
Adjusted OR
(95% CI)1
Adjusted
p value1
Spain
PDE4D rs1396476 SNP89 T 0.214 17.1 13.3 0.74 (0.56–0.99) 0.043* 0.70 (0.51–0.96) 0.026*
PDE4D rs2910829 SNP87 C 0.118 44.4 48.1 1.16 (0.94–1.43) 0.167 1.19 (0.95–1.50) 0.124
PDE4D rs702553 SNP56 T 0.923 31.9 31.1 1.03 (0.82–1.30) 0.768 1.06 (0.83–1.35) 0.652
PDE4D rs152312 SNP41 T 0.408 14.4 9.9 1.54 (0.72–3.27) 0.262 2.44 (0.94–6.31) 0.067
PDE4D rs12188950 SNP45 T 0.998 14.1 14.2 0.99 (0.72–1.34) 0.932 0.92 (0.66–1.27) 0.600
ALOX5AP rs10507391 SG13S114 T 0.118 58.6 63.4 1.22 (0.98–1.53) 0.070 1.15 (0.91–1.45) 0.249
Portugal
PDE4D rs1396476 SNP89 T 0.787 13.4 14.8 1.13 (0.88–1.45) 0.339 1.09 (0.76–1.54) 0.647
PDE4D rs2910829 SNP87 C 0.228 45.8 47.5 1.07 (0.90–1.28) 0.443 1.10 (0.86–1.41) 0.435
PDE4D rs702553 SNP56 T 0.941 32.1 35 0.87 (0.72–1.06) 0.163 0.96 (0.74–1.25) 0.770
PDE4D rs152312 SNP41 T 0.726 11.3 14.1 0.77 (0.51–1.17) 0.221 0.72 (0.42–1.21) 0.214
PDE4D rs12188950 SNP45 T 0.0001* 12.5 15.2 0.80 (0.62–1.03) 0.081 0.68 (0.48–0.97) 0.036*
ALOX5AP rs10507391 SG13S114 T 0.120 58.2 62.8 1.21 (1.01–1.46) 0.037* 1.30 (1.01–1.68) 0.041*
Overall
PDE4D rs1396476 SNP89 T 0.709 14.6 14.1 0.95 (0.79–1.15) 0.621 0.91 (0.74–1.12) 0.391
PDE4D rs2910829 SNP87 C 0.006* 45.3 47.8 1.10 (0.97–1.26) 0.143 1.15 (0.99–1.34) 0.062
PDE4D rs702553 SNP56 T 0.600 32.0 33.1 0.95 (0.82–1.10) 0.506 0.98 (0.84–1.15) 0.844
PDE4D rs152312 SNP41 T 0.826 12.0 13.4 0.89 (0.62–1.27) 0.514 0.99 (0.65–1.52) 0.976
PDE4D rs12188950 SNP45 T <0.001* 13.0 14.7 0.87 (0.71–1.05) 0.154 0.84 (0.67–1.04) 0.106
ALOX5AP rs10507391 SG13S114 T 0.514 58.3 63.1 1.22 (1.06–1.40) 0.004* 1.22 (1.04–1.42) 0.013*
S tatistically significant p values are marked with an asterisk. dbSNP ID = Identification number in the dbSNP database. 
1 Logistic regression adjusted for sex, age, diabetes, smoking and hypertension.
Table 3.  Meta-analysis results of the six SNPs in PDE4D and ALOX5AP with IS in the Spanish and Portuguese subsets
Gene SNP ID Allele Number
of case 
alleles
Number
of control 
alleles
Frequency 
cases
%
Frequency 
controls
%
Hetero-
geneity
I2
Hetero-
geneity 
p value
Per allele 
OR (95% CI)
p value
PDE4D rs1396476 T 2,034 1,550 14.06 14.65 0.75 0.031* 0.92 (0.61–1.39) 0.698
PDE4D rs2910829 C 2,002 1,514 47.80 45.31 0.00 0.566 1.11 (0.97–1.27) 0.140
PDE4D rs702553 T 1,930 1,510 66.94 68.01 0.19 0.257 0.94 (0.80–1.11) 0.449
PDE4D rs152312 T 1,056 374 13.35 12.03 0.59 0.117 0.99 (0.51–1.91) 0.974
PDE4D rs12188950 T 1,998 1,490 14.71 13.02 0.08 0.296 1.15 (0.94–1.41) 0.186
ALOX5AP rs10507391 T 1,898 1,490 63.12 58.32 0.00 0.950 1.22 (1.06–1.40) 0.006*
S tatistically significant p values are marked with an asterisk. Columns 8 and 9: inconsistency between studies.
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CI: 1.06–1.40, p = 0.004) and after logistic regression for 
classical stroke risk factors (OR = 1.22, 95% CI: 1.04–1.42, 
p = 0.013).
 We next performed a meta-analysis of both Spanish 
and Portuguese studies ( table  3 ), which indicated that 
overall the T allele of the SG13S114 SNP in  ALOX5AP was 
indeed a risk factor for IS and this association survived 
the Bonferroni correction for multiple testing (OR = 1.22, 
95% CI: 1.06–1.40, p = 0.006). The heterogeneity between 
the two subsets for this SNP was low (I 2 = 0.00, p = 0.950). 
None of the SNPs studied in the  PDE4D gene was associ-
ated with IS in the meta-analysis.
 Meta-Analysis 
 A flow diagram of the study selection process for the 
meta-analysis of the ALOX5AP gene is presented in  fig-
ure 1 . We performed a meta-analysis on studies carried 
out in White samples, including our data and 9 studies 
on  ALOX5AP  ( table 4 ). The analysis included data on two 
haplotypes and five out of twelve SNPs studied in cited 
papers for which data was available from at least two in-
dependent studies ( table 5 ). The highest number of sub-
jects was obtained from five different studies for the 
SG13S114 SNP, with 3,318 case alleles and 2,923 control 
alleles. The meta-analysis results indicate that this SNP is 
associated with IS (OR = 1.18, 95% CI: 1.07–1.31, p = 
0.001), in concordance with the results obtained in our 
population ( fig. 2 ). Moreover, the heterogeneity between 
studies was low (p = 0.896).
 Gene Expression Analysis 
 Expression of the ALOX5AP gene was determined in 
19 controls and 22 IS cases ( fig. 3 ). A significant difference 
in the mean relative levels of RNA expression could be 
observed between controls and cases (p = 0.003), IS cases 
showing higher levels (280  8 240%) than controls (140 
 8 130%). Moreover, in the control group, RNA levels de-
pend on the genotype of the SG13S114SNP (p = 0.001), 
AA carriers (260  8 100%; n = 5) presenting higher levels 
than AT carriers (110  8 120%; n = 8), which in turn pre-
sented higher levels than TT carriers (80  8 90%; n = 6). 
However, no association between  ALOX5AP RNA levels 
and SG13S114 genotype could be observed in the group 
of IS cases (p = 0.866). Levels of expression did not differ 
between controls (260  8 100%; n = 5) and cases (310  8 
310%; n = 7) carrying the AA genotype (p = 0.660). But 
we did observe an increase in the relative levels of T allele 
carriers between controls (100  8 110%; n = 14) and IS 
cases (260  8 210%; n = 15) (p  ! 0.001).
References excluded: n = 18
Non-human studies (n = 1)
No genetic analysis (n = 6)
Not neurovascular or cardiovascular disease (n = 11)
Unique reference identified: n = 58
References excluded: n = 31
Not ischemic stroke (n = 10)
Reviews (n = 13)
Case series, case reports (n = 1)
No original data (n = 0)
Non-European descent (n = 7)
Potentially relevant articles identified
for further review: n = 40
Final studies: n = 9
 Fig. 1. Flow diagram of the study selection 
process for the  ALOX5AP meta-analysis. 
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 Discussion 
 The design of the present study constitutes a three-
step approach. First of all, we selected some of the most 
interesting SNPs that were associated with stroke in the 
DeCode study in an Icelandic population. These SNPs 
were examined through case-control analysis in a large 
Iberian sample, a population that has never been tested 
before for association with the ALOX5AP and PDE4D 
genes. The data obtained were then included in a new 
and complete meta-analysis of white ancestry case-con-
trol studies with additional markers and haplotypes. Fi-
nally, functional studies were performed through gene 
expression analysis. We identified the SG13S114 SNP of 
the ALOX5AP gene as an independent risk factor for 
stroke, both in the case-control study in our population 
and in the meta-analysis of White ethnicity populations 
and show that this polymorphism regulates  ALOX5AP 
 RNA levels.
 The T allele of the SG13S114 variant is part of the 
HapA haplotype markers that was described as a risk fac-
tor for IS in the original study. The only study that ana-
lyzed the effect of the SG13S114 SNP in a European pop-
ulation observed identical results, which are that the T 
allele of this polymorphism is associated with a higher 
risk of IS  [7] . Kaushal et al.  [8] , in an American White 
population, also replicated the association of  ALOX5AP 
with IS, but not of the SG13S114 SNP. However, the fre-
quency of this SNP in their population was quite differ-
ent, indicating that the White American and the White 
European population frequencies are not comparable. 
This could explain the fact that two other studies in 
American White populations did not observe an associa-
tion of the SG13S114 SNP with IS  [10, 11] . Other studies 
Table 4.  Case-control studies on the association of ALOX5AP with IS in White populations
PubMed ID Country Year First author Journal Total number
of subjects
14770184 Iceland 2004 Helgadottir Nature Genetics 1,326
15640973 Scotland 2005 Helgadottir American Journal of Human Genetics 1,160
15731479 Germany 2005 Lohmussaar Stroke 1,375
16130105 USA 2005 Meschia Annals of Neurology 640
16778124 USA 2006 Zee Stroke 518
17387518 USA 2007 Kaushal Human Genetics 839
17655870 Sweden 2007 Kostulas Journal of Neurological Sciences 1,436
18398440 Sweden 2008 Lövkvist European Journal of Human Genetics 1,321
18323512 UK 2008 Bevan Stroke 1,805
Table 5.  Meta-analysis of the association of ALOX5AP variants with IS in White populations
SNP ID Number
of studies
Number
of case
alleles
Number
of control
alleles
RAF
cases
RAF
controls
Hetero-
geneity
I2
Hetero-
geneity
p value
Per allele
OR (95% CI)
p value
SG13S25 4 2,100 1,588 10.3 9.5 0.00 0.783 1.12 (0.89–1.40) 0.337
SG13S32 3 1,154 1,227 51.5 50.3 0.00 0.648 1.05 (0.89–1.23) 0.551
SG13S89 5 2,294 2,372 7.0 4.5 0.63 0.028* 1.54 (0.99–2.39) 0.055
SG13S106 2 511 491 68.7 66.8 0.67 0.082 1.10 (0.69–1.74) 0.694
SG13S114 5 3,318 2,923 65.2 61.6 0.00 0.896 1.18 (1.07–1.31) 0.001*
HapA 4 2,018 2,302 15.4 13.4 0.64 0.040* 1.18 (0.88–1.58) 0.266
HapB 3 1,341 1,593 7.1 6.5 0.00 0.692 1.08 (0.81–1.44) 0.623
S tatistically significant p values are marked with an asterisk. RAF = Risk allele frequency. Columns 7 and 8: inconsistency between 
studies.
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published a replication of the association of  ALOX5AP 
with IS, but did not study or publish the results obtained 
for this particular SG13S114 SNP  [6, 9] . Also, two studies 
investigated either other variants in the gene or the HapA 
directly  [12, 13] . Considering other ethnicities, two stud-
ies in Chinese populations also support a role for the
ALOX5AP gene in IS  [27, 28] .
 To definitively elucidate the contribution of the 
SG13S114 variant on the risk of stroke in white popula-
tions, we performed a new meta-analysis, including all 
data available in the literature and our own results. Meta-
analyses are statistical tools that permit to combine the 
results of several studies that address the same hypothesis. 
It is widely considered that resulting overall averages are 
more powerful estimates of the true effect size than those 
derived from a single study under a given single set of as-
sumptions and conditions, if study characteristics are well 
controlled. Our meta-analysis on the ALOX5AP gene 
confirmed that the SG13S114 SNP is associated with IS, in 
concordance with the results obtained in our population.
 The putative function of the SG13S114 variant is un-
known since it is located in an intronic region, but we 
demonstrate here that RNA levels depend on the geno-
types of this SNP in our control group. No study has ex-
plored the possible function of the ALOX5AP gene before 
on stroke. Therefore we decided to investigate the expres-
sion levels of this gene in more than 40 samples and 
showed that T allele carriers of the SG13S114 SNP present 
lower levels of ALOX5AP gene expression, which might 
indicate that low RNA levels of  ALOX5AP is a risk factor 
for IS. This gene encodes the 5-lipoxygenase activating 
protein (FLAP), a protein for which the only known role 
is the involvement in the initial step of leukotriene bio-
synthesis, a process that can be completely inhibited by 
compounds that bind FLAP. More specifically, mem-
brane-embedded FLAP, which has no known enzymatic 
activity, selectively transfers arachidonic acid to 5-lipoxy-
genase and enhances sequential oxygenation of arachi-
donic acid to 5(S)-hydroperoxyeicosatetraenoic acid and 
dehydration to leukotriene A 4  [29] . Leukotriene A 4 can 
then be converted either to pro-inflammatory leukotri-
ene B 4 or to the bronchoconstrictive, vasoconstrictive 
and pro-inflammatory cysteinyl leukotrienes. Those pro-
Study OR (95% CI) p value Weight %
Kaushal et al. [8] 1.17 (0.80–1.72) 0.405 6.2
Zee et al. [11] 1.00 (0.70–1.43) 1.000 7.0
Lõhmussaar et al. [7] 1.18 (1.00–1.38) 0.046* 35.0
Meschia et al. [10] 1.16 (0.78–1.72) 0.459 5.7
Domingues-Montanari et al. [2] 1.22 (1.06–1.41) 0.004* 46.1
Overall (95% CI) 1.18 (1.07–1.31) <0.001*
0.10 1.00 10.00
OR
 Fig. 2. Forest plot for carriers of the T allele of the SG13S114 SNP in the ALOX5AP gene. * Statistically signifi-
cant p value. 
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inflammatory effects of FLAP and the production of re-
active molecules such as superoxide anions  [6] have been 
linked to respiratory diseases, allergic diseases and car-
diovascular diseases. The ALOX5AP gene has also been 
linked to the risk of stroke, restenosis, myocardial infarc-
tion and atherosclerosis. It was shown that male carriers 
of the HapA at-risk haplotype had significantly greater 
production of leukotriene B 4 in neutrophils  [5] .
 In our study, we observed higher ALOX5AP gene ex-
pression levels in IS cases than in controls, although in 
the cases, RNA levels did not depend on the genotype of 
the SG13S114 SNP. This might indicate that during the 
acute phase of an IS,  ALOX5AP levels are increased, prob-
ably as part of the inflammation process. This is support-
ed by the fact that T carriers in cases present statistically 
higher levels of  ALOX5AP RNA than T carriers in con-
trols. The lack of association with the genotype in the IS 
cases could be due to a general increase in RNA levels, 
masking the effect of the polymorphism. However, our 
analysis presents several limitations, such as the small 
sample size, the difficulty to access brain infarcted tissue 
and the widespread alteration of mRNA levels across dif-
ferent gene and gene sets in diseased individuals, which 
limit the relevance of these results. We do not have results 
of  ALOX5AP RNA levels in other time points than the 
acute phase but considering the results in the control 
group, we assume that the T allele is associated with low 
RNA levels. We hypothesize that these low RNA levels 
might be a risk factor for IS, for example by altering the 
inflammatory response, thus playing a role in neuro- and 
cardiovascular diseases. However, more studies are need-
ed to demonstrate this hypothesis.
 Concerning the PDE4D gene, we found no associa-
tion of the five SNPs analyzed in the PDE4D gene with 
the risk of IS in our population, although some SNPs did 
not respect the HWE and thus question the veracity of 
those results. Bevan et al.  [9] , similarly to our findings, 
showed that no genetic variant presented a strong and 
consistent association to IS, suggesting that the associa-
tions observed in Iceland for the PDE4D gene might be 
restricted only to specific populations. We also per-
formed a new and complete meta-analysis of white an-
cestry case-control studies of the PDE4D gene in IS, but 
we did not observe any association (data not shown). 
However, a recent study on the differential expression of 
genes upon acute IS in human peripheral blood mono-
nuclear cells showed that expression profiles were the 
most significantly different between IS patients and 
healthy subjects for the PDE4D gene out of around 
10,000 probe sets  [30] .
 Most studies published as a follow-up to the original 
article present limitations in the number of variants test-
ed, small size of samples analyzed and the subtyping of 
the different etiologies of stroke  [31, 32] . In our case, tech-
nical difficulties prevented the analysis of more variants, 
including the other SNPs constituting the HapA haplo-
type of the ALOX5AP gene, as well as the AC008818-1 
microsatellite in the PDE4D gene, which were associated 
with stroke in the initial paper. Moreover, subtype analy-
sis of the patients would have been very interesting since 
phenotypic differences among IS patients is mainly re-
lated to different stroke etiologies; unfortunately TOAST 
information was not available for all cases, limiting sub-
typing to a small number of subjects. Population stratifi-
cation might also be a source of replication failure. On the 
other hand, the overall sample size used was considered 
sufficient to observe a variation of at least 0.06 in the mi-
nor allele frequency of any SNP between cases and con-
trols with a significance level of 0.05 and a power of 0.80. 
Also, the interaction with other traditional risk factors 
was well controlled. Considering the results of the meta-
analysis, publication bias is an important potential con-
founding factor. However, heterogeneity between studies 
was well assessed statistically with random effects anal-
ysis.
 Summary 
 In conclusion, the present study is the first to investi-
gate the role of the PDE4D and ALOX5AP genes on the 
risk of developing IS in an Iberian population, indicating 
that the T allele of the SG13S114 genetic variant in the 
ALOX5AP gene is an independent risk factor for IS and 
is associated with  ALOX5AP expression levels. Moreover, 
we present here the results of a new large meta-analysis 
on the ALOX5AP gene in IS, comprising 3,318 case alleles 
and 2,923 control alleles, showing that the SG13S114 SNP 
is a risk factor for IS in White populations. The role of this 
gene in stroke merits further investigation. 
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